http://142-54-23-223.fusionmedialtd.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 24 Jul 2026 08:00:35 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://142-54-23-223.fusionmedialtd.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Estrella+Immunopharma+doses+first+patient+in+EB103+expansion+trial/26810875.html <p>Estrella Immunopharma, Inc. (NASDAQ: ESLA) announced that the first patient has been dosed in the dose-expansion phase of its STARLIGHT-1 Phase I/II clinical trial, which is evaluating EB103, a CD19-redirected T-cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).</p><p>The expansion phase follows data from the dose-escalation cohort showing that, at a six-month assessment of evaluable Phase I patients without central nervous system involvement, all patients who achieved a complete response remained in complete response.</p><p>"This marks an important milestone for Estrella and STARLIGHT-1," said Cheng Liu, PhD, Chief Executive Officer of Estrella. "The sustained complete responses observed to http://www.streetinsider.com/Corporate+News/Estrella+Immunopharma+doses+first+patient+in+EB103+expansion+trial/26810875.html Fri, 24 Jul 2026 08:00:35 -0400 ESLA http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Announces+First+Patient+Dosed+in+Dose-Expansion+Phase+of+STARLIGHT-1+Trial+and+Reports+Durable+Response+Rate+in+Advanced+B-Cell+Non-Hodgkin%E2%80%99s+Lymphoma/26810847.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that the first patient has been successfully dosed in the dose-expansion phase of its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with relapsed/refractory (R/R) B-cell non-Hodgkin’s lymphoma (NHL). </p><p> Estrella’s dosing of the first patient in the dose-expansion cohort follows encouraging efficacy data from the dose-escalation cohort. At the 6-month assessment of evaluable Phase I patients with no CNS involvement, http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Announces+First+Patient+Dosed+in+Dose-Expansion+Phase+of+STARLIGHT-1+Trial+and+Reports+Durable+Response+Rate+in+Advanced+B-Cell+Non-Hodgkin%E2%80%99s+Lymphoma/26810847.html Fri, 24 Jul 2026 08:00:00 -0400 A.50214643 ESLA O.35847762 O.52433315 http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Announces+First+Patient+Dosed+in+Dose-Expansion+Phase+of+STARLIGHT-1+Trial+and+Reports+Durable+Response+Rate+in+Advanced+B-Cell+Non-Hodgkin%E2%80%99s+Lymphoma/26810847.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that the first patient has been successfully dosed in the dose-expansion phase of its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with relapsed/refractory (R/R) B-cell non-Hodgkin’s lymphoma (NHL). </p><p> Estrella’s dosing of the first patient in the dose-expansion cohort follows encouraging efficacy data from the dose-escalation cohort. At the 6-month assessment of evaluable Phase I patients with no CNS involvement, http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Announces+First+Patient+Dosed+in+Dose-Expansion+Phase+of+STARLIGHT-1+Trial+and+Reports+Durable+Response+Rate+in+Advanced+B-Cell+Non-Hodgkin%E2%80%99s+Lymphoma/26810847.html Fri, 24 Jul 2026 08:00:00 -0400 A.50214643 ESLA O.35847762 O.52433315 http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Announces+First+Patient+Dosed+in+Dose-Expansion+Phase+of+STARLIGHT-1+Trial+and+Reports+Durable+Response+Rate+in+Advanced+B-Cell+Non-Hodgkin%E2%80%99s+Lymphoma/26810847.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that the first patient has been successfully dosed in the dose-expansion phase of its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with relapsed/refractory (R/R) B-cell non-Hodgkin’s lymphoma (NHL). </p><p> Estrella’s dosing of the first patient in the dose-expansion cohort follows encouraging efficacy data from the dose-escalation cohort. At the 6-month assessment of evaluable Phase I patients with no CNS involvement, http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Announces+First+Patient+Dosed+in+Dose-Expansion+Phase+of+STARLIGHT-1+Trial+and+Reports+Durable+Response+Rate+in+Advanced+B-Cell+Non-Hodgkin%E2%80%99s+Lymphoma/26810847.html Fri, 24 Jul 2026 08:00:00 -0400 A.50214643 ESLA O.35847762 O.52433315 http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Announces+First+Patient+Dosed+in+Dose-Expansion+Phase+of+STARLIGHT-1+Trial+and+Reports+Durable+Response+Rate+in+Advanced+B-Cell+Non-Hodgkin%E2%80%99s+Lymphoma/26810847.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that the first patient has been successfully dosed in the dose-expansion phase of its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with relapsed/refractory (R/R) B-cell non-Hodgkin’s lymphoma (NHL). </p><p> Estrella’s dosing of the first patient in the dose-expansion cohort follows encouraging efficacy data from the dose-escalation cohort. At the 6-month assessment of evaluable Phase I patients with no CNS involvement, http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Announces+First+Patient+Dosed+in+Dose-Expansion+Phase+of+STARLIGHT-1+Trial+and+Reports+Durable+Response+Rate+in+Advanced+B-Cell+Non-Hodgkin%E2%80%99s+Lymphoma/26810847.html Fri, 24 Jul 2026 08:00:00 -0400 A.50214643 ESLA O.35847762 O.52433315 http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Announces+First+Patient+Dosed+in+Dose-Expansion+Phase+of+STARLIGHT-1+Trial+and+Reports+Durable+Response+Rate+in+Advanced+B-Cell+Non-Hodgkin%E2%80%99s+Lymphoma/26810847.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that the first patient has been successfully dosed in the dose-expansion phase of its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with relapsed/refractory (R/R) B-cell non-Hodgkin’s lymphoma (NHL). </p><p> Estrella’s dosing of the first patient in the dose-expansion cohort follows encouraging efficacy data from the dose-escalation cohort. At the 6-month assessment of evaluable Phase I patients with no CNS involvement, http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Announces+First+Patient+Dosed+in+Dose-Expansion+Phase+of+STARLIGHT-1+Trial+and+Reports+Durable+Response+Rate+in+Advanced+B-Cell+Non-Hodgkin%E2%80%99s+Lymphoma/26810847.html Fri, 24 Jul 2026 08:00:00 -0400 A.50214643 ESLA O.35847762 O.52433315 http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Announces+First+Patient+Dosed+in+Dose-Expansion+Phase+of+STARLIGHT-1+Trial+and+Reports+Durable+Response+Rate+in+Advanced+B-Cell+Non-Hodgkin%E2%80%99s+Lymphoma/26810847.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that the first patient has been successfully dosed in the dose-expansion phase of its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with relapsed/refractory (R/R) B-cell non-Hodgkin’s lymphoma (NHL). </p><p> Estrella’s dosing of the first patient in the dose-expansion cohort follows encouraging efficacy data from the dose-escalation cohort. At the 6-month assessment of evaluable Phase I patients with no CNS involvement, http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Announces+First+Patient+Dosed+in+Dose-Expansion+Phase+of+STARLIGHT-1+Trial+and+Reports+Durable+Response+Rate+in+Advanced+B-Cell+Non-Hodgkin%E2%80%99s+Lymphoma/26810847.html Fri, 24 Jul 2026 08:00:00 -0400 A.50214643 ESLA O.35847762 O.52433315 http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Announces+First+Patient+Dosed+in+Dose-Expansion+Phase+of+STARLIGHT-1+Trial+and+Reports+Durable+Response+Rate+in+Advanced+B-Cell+Non-Hodgkin%E2%80%99s+Lymphoma/26810847.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that the first patient has been successfully dosed in the dose-expansion phase of its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with relapsed/refractory (R/R) B-cell non-Hodgkin’s lymphoma (NHL). </p><p> Estrella’s dosing of the first patient in the dose-expansion cohort follows encouraging efficacy data from the dose-escalation cohort. At the 6-month assessment of evaluable Phase I patients with no CNS involvement, http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Announces+First+Patient+Dosed+in+Dose-Expansion+Phase+of+STARLIGHT-1+Trial+and+Reports+Durable+Response+Rate+in+Advanced+B-Cell+Non-Hodgkin%E2%80%99s+Lymphoma/26810847.html Fri, 24 Jul 2026 08:00:00 -0400 A.50214643 ESLA O.35847762 O.52433315 http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Announces+First+Patient+Dosed+in+Dose-Expansion+Phase+of+STARLIGHT-1+Trial+and+Reports+Durable+Response+Rate+in+Advanced+B-Cell+Non-Hodgkin%E2%80%99s+Lymphoma/26810847.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that the first patient has been successfully dosed in the dose-expansion phase of its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with relapsed/refractory (R/R) B-cell non-Hodgkin’s lymphoma (NHL). </p><p> Estrella’s dosing of the first patient in the dose-expansion cohort follows encouraging efficacy data from the dose-escalation cohort. At the 6-month assessment of evaluable Phase I patients with no CNS involvement, http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Announces+First+Patient+Dosed+in+Dose-Expansion+Phase+of+STARLIGHT-1+Trial+and+Reports+Durable+Response+Rate+in+Advanced+B-Cell+Non-Hodgkin%E2%80%99s+Lymphoma/26810847.html Fri, 24 Jul 2026 08:00:00 -0400 A.50214643 ESLA O.35847762 O.52433315 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Estrella+Immunopharma%2C++++For%3A+Jun+29/26714992.html si-local-file:///var/storage/secattach/20260630/26714992.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Estrella+Immunopharma%2C++++For%3A+Jun+29/26714992.html Tue, 30 Jun 2026 17:30:00 -0400 ESLA O.52433315 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Estrella+Immunopharma%2C++++For%3A+Jun+29/26714992.html si-local-file:///var/storage/secattach/20260630/26714992.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Estrella+Immunopharma%2C++++For%3A+Jun+29/26714992.html Tue, 30 Jun 2026 17:30:00 -0400 ESLA O.52433315 http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++Estrella+Immunopharma%2C++++For%3A+Jun+29/26559212.html si-local-file:///var/storage/secattach/20260527/26559212.html http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++Estrella+Immunopharma%2C++++For%3A+Jun+29/26559212.html Wed, 27 May 2026 17:26:00 -0400 ESLA O.52433315 http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++Estrella+Immunopharma%2C++++For%3A+Jun+29/26559212.html si-local-file:///var/storage/secattach/20260527/26559212.html http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++Estrella+Immunopharma%2C++++For%3A+Jun+29/26559212.html Wed, 27 May 2026 17:26:00 -0400 ESLA O.52433315 http://www.streetinsider.com/SEC+Filings/Form++NT+10-Q++++Estrella+Immunopharma%2C++++For%3A+Mar+31/26509663.html si-local-file:///var/storage/secattach/20260518/26509663.html http://www.streetinsider.com/SEC+Filings/Form++NT+10-Q++++Estrella+Immunopharma%2C++++For%3A+Mar+31/26509663.html Mon, 18 May 2026 06:04:00 -0400 ESLA O.52433315 http://www.streetinsider.com/SEC+Filings/Form++NT+10-Q++++Estrella+Immunopharma%2C++++For%3A+Mar+31/26509663.html si-local-file:///var/storage/secattach/20260518/26509663.html http://www.streetinsider.com/SEC+Filings/Form++NT+10-Q++++Estrella+Immunopharma%2C++++For%3A+Mar+31/26509663.html Mon, 18 May 2026 06:04:00 -0400 ESLA O.52433315 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Estrella+Immunopharma%2C++++For%3A+Mar+31/26509670.html si-local-file:///var/storage/secattach/20260518/26509670.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Estrella+Immunopharma%2C++++For%3A+Mar+31/26509670.html Mon, 18 May 2026 06:04:00 -0400 ESLA O.52433315 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Estrella+Immunopharma%2C++++For%3A+Mar+31/26509670.html si-local-file:///var/storage/secattach/20260518/26509670.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Estrella+Immunopharma%2C++++For%3A+Mar+31/26509670.html Mon, 18 May 2026 06:04:00 -0400 ESLA O.52433315 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Estrella+Immunopharma%2C+++++++++++++++++Filed+by%3A+ARMISTICE+CAPITAL%2C+LLC/26502058.html si-local-file:///var/storage/secattach/20260515/26502058.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Estrella+Immunopharma%2C+++++++++++++++++Filed+by%3A+ARMISTICE+CAPITAL%2C+LLC/26502058.html Fri, 15 May 2026 11:16:00 -0400 ESLA O.52433315 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Estrella+Immunopharma%2C+++++++++++++++++Filed+by%3A+ARMISTICE+CAPITAL%2C+LLC/26502058.html si-local-file:///var/storage/secattach/20260515/26502058.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Estrella+Immunopharma%2C+++++++++++++++++Filed+by%3A+ARMISTICE+CAPITAL%2C+LLC/26502058.html Fri, 15 May 2026 11:16:00 -0400 ESLA O.52433315 http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+to+Participate+in+the+D.+Boral+Capital+Global+Conference/26430113.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that its CEO and CFO will participate in one-on-one investor meetings at the D. Boral Capital 2026 Global Conference. </p><p> Hosted by D. Boral Capital, this curated forum at The Plaza Hotel brings together executives from emerging-growth public and private companies to engage directly with institutional investors and strategic partners. </p><p> <b>Date: </b>May 7, 2026 <br /><b>Venue: </b>The Plaza Hotel, New York, NY <br /><b>Website: </b><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4673396-1%26h%3D1404733027%26u%3Dhttps%253A%252F%252Fwww.globenewswire.com%252FTracker%253Fdata%253DhVey1IWEOdoWnKr8esNaiTnX4SAPxvUvELUOxTXmnH_7yIvl8Tf4_7uJ6ELQTfKt1XEBPpxCkgKsELVOXQGbArrBhOX-0m-Lit1NHXJS2QIFzqEiS6CMK06oeQMmQwtcZgmiMmzPvmhW1GXhBIdVOjInSU52VOGdZyVBLN-SvZ8%253D%26a%3Dhttps%253A%252F%252Fdboralcapital.com%252Fconference%252F&amp;esheet=54528990&amp;newsitemid=20260505375885&amp;lan=en-US&amp;anchor=https%3A%2F%2Fdboralcapital.com%2Fconference&amp;index=1&amp;md5=56f1aa5cffc4f9f3253ff8543a175340" shape="rect"><b>https://dboralcapital.com/conference</b></a> </p><p> Investors interested http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+to+Participate+in+the+D.+Boral+Capital+Global+Conference/26430113.html Tue, 05 May 2026 08:00:00 -0400 ESLA ESLAW O.52433315 http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+to+Participate+in+the+D.+Boral+Capital+Global+Conference/26430113.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that its CEO and CFO will participate in one-on-one investor meetings at the D. Boral Capital 2026 Global Conference. </p><p> Hosted by D. Boral Capital, this curated forum at The Plaza Hotel brings together executives from emerging-growth public and private companies to engage directly with institutional investors and strategic partners. </p><p> <b>Date: </b>May 7, 2026 <br /><b>Venue: </b>The Plaza Hotel, New York, NY <br /><b>Website: </b><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4673396-1%26h%3D1404733027%26u%3Dhttps%253A%252F%252Fwww.globenewswire.com%252FTracker%253Fdata%253DhVey1IWEOdoWnKr8esNaiTnX4SAPxvUvELUOxTXmnH_7yIvl8Tf4_7uJ6ELQTfKt1XEBPpxCkgKsELVOXQGbArrBhOX-0m-Lit1NHXJS2QIFzqEiS6CMK06oeQMmQwtcZgmiMmzPvmhW1GXhBIdVOjInSU52VOGdZyVBLN-SvZ8%253D%26a%3Dhttps%253A%252F%252Fdboralcapital.com%252Fconference%252F&amp;esheet=54528990&amp;newsitemid=20260505375885&amp;lan=en-US&amp;anchor=https%3A%2F%2Fdboralcapital.com%2Fconference&amp;index=1&amp;md5=56f1aa5cffc4f9f3253ff8543a175340" shape="rect"><b>https://dboralcapital.com/conference</b></a> </p><p> Investors interested http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+to+Participate+in+the+D.+Boral+Capital+Global+Conference/26430113.html Tue, 05 May 2026 08:00:00 -0400 ESLA ESLAW O.52433315 http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+to+Participate+in+the+D.+Boral+Capital+Global+Conference/26430113.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that its CEO and CFO will participate in one-on-one investor meetings at the D. Boral Capital 2026 Global Conference. </p><p> Hosted by D. Boral Capital, this curated forum at The Plaza Hotel brings together executives from emerging-growth public and private companies to engage directly with institutional investors and strategic partners. </p><p> <b>Date: </b>May 7, 2026 <br /><b>Venue: </b>The Plaza Hotel, New York, NY <br /><b>Website: </b><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4673396-1%26h%3D1404733027%26u%3Dhttps%253A%252F%252Fwww.globenewswire.com%252FTracker%253Fdata%253DhVey1IWEOdoWnKr8esNaiTnX4SAPxvUvELUOxTXmnH_7yIvl8Tf4_7uJ6ELQTfKt1XEBPpxCkgKsELVOXQGbArrBhOX-0m-Lit1NHXJS2QIFzqEiS6CMK06oeQMmQwtcZgmiMmzPvmhW1GXhBIdVOjInSU52VOGdZyVBLN-SvZ8%253D%26a%3Dhttps%253A%252F%252Fdboralcapital.com%252Fconference%252F&amp;esheet=54528990&amp;newsitemid=20260505375885&amp;lan=en-US&amp;anchor=https%3A%2F%2Fdboralcapital.com%2Fconference&amp;index=1&amp;md5=56f1aa5cffc4f9f3253ff8543a175340" shape="rect"><b>https://dboralcapital.com/conference</b></a> </p><p> Investors interested http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+to+Participate+in+the+D.+Boral+Capital+Global+Conference/26430113.html Tue, 05 May 2026 08:00:00 -0400 ESLA ESLAW O.52433315 http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+to+Participate+in+the+D.+Boral+Capital+Global+Conference/26430113.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that its CEO and CFO will participate in one-on-one investor meetings at the D. Boral Capital 2026 Global Conference. </p><p> Hosted by D. Boral Capital, this curated forum at The Plaza Hotel brings together executives from emerging-growth public and private companies to engage directly with institutional investors and strategic partners. </p><p> <b>Date: </b>May 7, 2026 <br /><b>Venue: </b>The Plaza Hotel, New York, NY <br /><b>Website: </b><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4673396-1%26h%3D1404733027%26u%3Dhttps%253A%252F%252Fwww.globenewswire.com%252FTracker%253Fdata%253DhVey1IWEOdoWnKr8esNaiTnX4SAPxvUvELUOxTXmnH_7yIvl8Tf4_7uJ6ELQTfKt1XEBPpxCkgKsELVOXQGbArrBhOX-0m-Lit1NHXJS2QIFzqEiS6CMK06oeQMmQwtcZgmiMmzPvmhW1GXhBIdVOjInSU52VOGdZyVBLN-SvZ8%253D%26a%3Dhttps%253A%252F%252Fdboralcapital.com%252Fconference%252F&amp;esheet=54528990&amp;newsitemid=20260505375885&amp;lan=en-US&amp;anchor=https%3A%2F%2Fdboralcapital.com%2Fconference&amp;index=1&amp;md5=56f1aa5cffc4f9f3253ff8543a175340" shape="rect"><b>https://dboralcapital.com/conference</b></a> </p><p> Investors interested http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+to+Participate+in+the+D.+Boral+Capital+Global+Conference/26430113.html Tue, 05 May 2026 08:00:00 -0400 ESLA ESLAW O.52433315 http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+to+Participate+in+the+D.+Boral+Capital+Global+Conference/26430113.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that its CEO and CFO will participate in one-on-one investor meetings at the D. Boral Capital 2026 Global Conference. </p><p> Hosted by D. Boral Capital, this curated forum at The Plaza Hotel brings together executives from emerging-growth public and private companies to engage directly with institutional investors and strategic partners. </p><p> <b>Date: </b>May 7, 2026 <br /><b>Venue: </b>The Plaza Hotel, New York, NY <br /><b>Website: </b><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4673396-1%26h%3D1404733027%26u%3Dhttps%253A%252F%252Fwww.globenewswire.com%252FTracker%253Fdata%253DhVey1IWEOdoWnKr8esNaiTnX4SAPxvUvELUOxTXmnH_7yIvl8Tf4_7uJ6ELQTfKt1XEBPpxCkgKsELVOXQGbArrBhOX-0m-Lit1NHXJS2QIFzqEiS6CMK06oeQMmQwtcZgmiMmzPvmhW1GXhBIdVOjInSU52VOGdZyVBLN-SvZ8%253D%26a%3Dhttps%253A%252F%252Fdboralcapital.com%252Fconference%252F&amp;esheet=54528990&amp;newsitemid=20260505375885&amp;lan=en-US&amp;anchor=https%3A%2F%2Fdboralcapital.com%2Fconference&amp;index=1&amp;md5=56f1aa5cffc4f9f3253ff8543a175340" shape="rect"><b>https://dboralcapital.com/conference</b></a> </p><p> Investors interested http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+to+Participate+in+the+D.+Boral+Capital+Global+Conference/26430113.html Tue, 05 May 2026 08:00:00 -0400 ESLA ESLAW O.52433315 http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+to+Participate+in+the+D.+Boral+Capital+Global+Conference/26430113.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that its CEO and CFO will participate in one-on-one investor meetings at the D. Boral Capital 2026 Global Conference. </p><p> Hosted by D. Boral Capital, this curated forum at The Plaza Hotel brings together executives from emerging-growth public and private companies to engage directly with institutional investors and strategic partners. </p><p> <b>Date: </b>May 7, 2026 <br /><b>Venue: </b>The Plaza Hotel, New York, NY <br /><b>Website: </b><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4673396-1%26h%3D1404733027%26u%3Dhttps%253A%252F%252Fwww.globenewswire.com%252FTracker%253Fdata%253DhVey1IWEOdoWnKr8esNaiTnX4SAPxvUvELUOxTXmnH_7yIvl8Tf4_7uJ6ELQTfKt1XEBPpxCkgKsELVOXQGbArrBhOX-0m-Lit1NHXJS2QIFzqEiS6CMK06oeQMmQwtcZgmiMmzPvmhW1GXhBIdVOjInSU52VOGdZyVBLN-SvZ8%253D%26a%3Dhttps%253A%252F%252Fdboralcapital.com%252Fconference%252F&amp;esheet=54528990&amp;newsitemid=20260505375885&amp;lan=en-US&amp;anchor=https%3A%2F%2Fdboralcapital.com%2Fconference&amp;index=1&amp;md5=56f1aa5cffc4f9f3253ff8543a175340" shape="rect"><b>https://dboralcapital.com/conference</b></a> </p><p> Investors interested http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+to+Participate+in+the+D.+Boral+Capital+Global+Conference/26430113.html Tue, 05 May 2026 08:00:00 -0400 ESLA ESLAW O.52433315